Phase 1 Refractory Hodgkin Lymphoma Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting
Phase 1
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Advanced Solid TumorRefractory Hodgkin Lymphoma
FBD Biologics Limited50 enrolled7 locationsNCT06487624
Recruiting
Phase 1Phase 2
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital100 enrolled1 locationNCT05896046